The Host Genetics, Immunology and Virology of HIV Study (Formerly ‘International HIV Controller Study’)

Written by webmaster
Monday, 11 October 2010 19:29
The Host Genetics, Immunology and Virology of HIV Study (Formerly ‘International HIV Controller Study’) Ragon Institute of MGH, MIT & Harvard (Formerly ‘Partners AIDS Research Center’) Massachusetts General Hospital Principal Investigator: Bruce D. Walker, M.D. Director, Ragon Institute Co-Investigator: Florencia Pereyra, M.D. Pamela A. Richtmyer, Clinical Research Project Manager 617-726-8099 This e-mail address is being protected from spambots. You need JavaScript enabled to view it Kristin Moss, Research Coordinator 617-643-3643 This e-mail address is being protected from spambots. You need JavaScript enabled to view it Alice Tsao, Research Assistant 617-643-2368 This e-mail address is being protected from spambots. You need JavaScript enabled to view it www.hivcontrollers.org www.ragoninstitute.org
Last Updated ( Monday, 11 October 2010 19:34 )

Please make a tax deductible donation to Zephyr LTNP Foundation, a 501(c)(3) entity via Paypal. No Paypal account required.

Wednesday 9th March 2011
This is our final bulletin from CROI 2011. We hope you have found our news coverage useful. You can find all our coverage at www.aidsmap.com/croi2011, including the news reports and bulletins.We are always looking for ways of improving and developing our resources – so if you have any comments that you would like
Thursday 3rd March 2011
There is increasing evidence of the transmission of HIV strains with resistance to anti-HIV drugs in low- and middle-income countries. Research in eleven sub-Saharan African countries showed that the chances of detecting transmitted resistance increased by over a third each year that a country had been scaling up HIV treatment. A separate study involving people recently diagnosed
Wednesday 2nd March 2011
A new type of anti-HIV drug that targets the first step in HIV’s entry into cells has done well in a Phase IIa study. Currently known as BMS-663068, the drug was shown to be safe and to work against the virus. HIV cell entry is a three-step process. The virus must first attach to the